X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs GLENMARK PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS GLENMARK PHARMA NOVARTIS/
GLENMARK PHARMA
 
P/E (TTM) x 392.7 14.2 2,765.1% View Chart
P/BV x 19.3 3.8 515.3% View Chart
Dividend Yield % 1.5 0.3 463.8%  

Financials

 NOVARTIS   GLENMARK PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-16
GLENMARK PHARMA
Mar-17
NOVARTIS/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs982993 98.9%   
Low Rs556729 76.3%   
Sales per share (Unadj.) Rs252.9325.5 77.7%  
Earnings per share (Unadj.) Rs62.139.3 158.2%  
Cash flow per share (Unadj.) Rs63.348.7 130.1%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.30.2 559.8%  
Book value per share (Unadj.) Rs363.6159.2 228.4%  
Shares outstanding (eoy) m31.96282.17 11.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.02.6 115.0%   
Avg P/E ratio x12.421.9 56.5%  
P/CF ratio (eoy) x12.217.7 68.7%  
Price / Book Value ratio x2.15.4 39.1%  
Dividend payout %16.15.1 316.2%   
Avg Mkt Cap Rs m24,580242,991 10.1%   
No. of employees `0000.813.0 5.8%   
Total wages/salary Rs m1,80116,408 11.0%   
Avg. sales/employee Rs Th10,748.97,083.9 151.7%   
Avg. wages/employee Rs Th2,395.21,265.4 189.3%   
Avg. net profit/employee Rs Th2,641.1855.1 308.9%   
INCOME DATA
Net Sales Rs m8,08391,857 8.8%  
Other income Rs m829374 222.0%   
Total revenues Rs m8,91392,230 9.7%   
Gross profit Rs m23420,367 1.1%  
Depreciation Rs m372,644 1.4%   
Interest Rs m22,373 0.1%   
Profit before tax Rs m1,02515,724 6.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,696-810 -209.5%   
Tax Rs m7523,827 19.7%   
Profit after tax Rs m1,98611,088 17.9%  
Gross profit margin %2.922.2 13.1%  
Effective tax rate %73.424.3 301.4%   
Net profit margin %24.612.1 203.6%  
BALANCE SHEET DATA
Current assets Rs m12,67868,746 18.4%   
Current liabilities Rs m2,43327,027 9.0%   
Net working cap to sales %126.745.4 279.1%  
Current ratio x5.22.5 204.9%  
Inventory Days Days3385 38.5%  
Debtors Days Days2296 23.5%  
Net fixed assets Rs m6924,132 0.3%   
Share capital Rs m160282 56.6%   
"Free" reserves Rs m11,46044,643 25.7%   
Net worth Rs m11,62144,925 25.9%   
Long term debt Rs m045,363 0.0%   
Total assets Rs m14,400117,639 12.2%  
Interest coverage x570.57.6 7,481.4%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x0.60.8 71.9%   
Return on assets %13.811.4 120.7%  
Return on equity %17.124.7 69.2%  
Return on capital %23.619.1 123.1%  
Exports to sales %0.70-   
Imports to sales %18.60-   
Exports (fob) Rs m60NA-   
Imports (cif) Rs m1,503NA-   
Fx inflow Rs m18656,152 0.3%   
Fx outflow Rs m1,8218,084 22.5%   
Net fx Rs m-1,63548,068 -3.4%   
CASH FLOW
From Operations Rs m2,5316,574 38.5%  
From Investments Rs m-8,270-7,124 116.1%  
From Financial Activity Rs m-3865,432 -7.1%  
Net Cashflow Rs m-6,1251,992 -307.4%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 6.9 29.0%  
FIIs % 1.6 34.4 4.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 10.5 204.8%  
Shareholders   41,647 56,727 73.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   GSK PHARMA  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  IPCA LABS  NATCO PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jan 22, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS